ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy drug dostarlimab takes on chemo in advanced endometrial cancer trial
Disease control OngoingThis phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or prevent cancer from returning in people with recurrent endometrial cancer. About 24 participants will receive the combination. The study compares this com…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC